Sandhya Girish

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Coronavirus Disease

Epidermal Growth Factor Receptor

Top Venues

Clinical pharmacology and therapeutics

Cancer chemotherapy and pharmacology

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Mohamed-Eslam F Mohamed, Sandhya Girish, Rita Humeniuk, Silpa Nuthalapati, Amit Desai, Amita Datta-Mannan, Ferdous Gheyas, Jitendra Kanodia, Sravanthi Cheeti, Tong Zhu
Impact of COVID-19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective. Clinical pharmacology and therapeutics (2024)
Mohamed-Eslam F Mohamed, Sandhya Girish, Rita Humeniuk, Silpa Nuthalapati, Amit Desai, Amita Datta-Mannan, Ferdous Gheyas, Jitendra Kanodia, Sravanthi Cheeti, Tong Zhu
Impact of COVID-19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective. Clinical pharmacology and therapeutics 116 (1) (2024)
Rita Humeniuk, Kavita Juneja, Shuguang Chen, Scott Ellis, Olena Anoshchenko, Deqing Xiao, Aaron Share, Matthew Johnston, Santosh Davies, Adam DeZure, Joe Llewellyn, Anu Osinusi, Helen Winter, Sandhya Girish, Ramesh Palaparthy, Mark Dresser
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants. Clinical and translational science (2023)
Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk, Matts Kågedal, Angelica L Quartino, Sandhya Girish, Chunze Li, Whitney P Kirschbrown
Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer chemotherapy and pharmacology (2021)
Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk, Matts Kågedal, Angelica L Quartino, Sandhya Girish, Chunze Li, Whitney P Kirschbrown
Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer chemotherapy and pharmacology 88 (3) (2021)